Tesamorelin for excess abdominal fat in HIV
Visceral adipose tissue decreased about 15.2% with tesamorelin versus an increase of about 5% with placebo.
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Adults with HIV and excess abdominal fat
n=412
Visceral adipose tissue decreased about 15.2% with tesamorelin versus an increase of about 5% with placebo.
Strong evidence for a narrow HIV-associated lipodystrophy indication; not proof of general weight-loss efficacy.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Visceral adipose tissue decreased about 15.2% with tesamorelin versus an increase of about 5% with placebo.